Hours after Allergan (NYSE:AGN) said it was considering an acquisition of Shire (NSDQ:SHPG), the Dublin-based company announced that it does not intend to make such an offer. Reports also surfaced today that Shire rejected a $63 billion takeover offer from Takeda Pharmaceutical (TYO:4502). Reuters, which first broke the news of Allergan’s interest in Shire, citing a pair of unnamed sources, […]
Ferring Pharma acquires Rebiotix and its microbiome therapy platform
Ferring Pharmaceuticals inked a deal to acquire Rebiotix and its platform of living drugs for an undisclosed amount, the companies announced today. The Roseville, Minn.-based company is developing a microbiome-based therapy to prevent recurrent Clostridium difficile infection. Its Microbiota Restoration Therapy, which is delivered via enema or a lyophilized, non-frozen oral capsule, is designed to supply a […]
Fagron combines with Humco and its drug-delivery tech in $70m deal
Pharmaceutical compounding company Fagron (EBR:FAGR) plans to combine with Humco and its portfolio of drug-delivery technology in a deal valued up to $70 million, the companies announced today. According to the agreement, Humco chairman & CEO Gregory Pulido will become executive chairman while Andrew Pulido, Humco’s president of global pharmaceuticals, will assume the role of president. “I […]
Johnson & Johnson moves closer to exiting the diabetes business with $2.1B LifeScan sale
Johnson & Johnson (NYSE:JNJ) took another step toward the exit door for the diabetes business, agreeing to a $2,1 billion offer from private equity shop Platinum Equity for its LifeScan blood glucose monitoring unit. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, Animas and Calibra Medical diabetes businesses and later […]
U.S., German antitrust authorities clear Varian’s $1.3B Sirtex buyout
U.S. antitrust authorities and the German Federal Cartel Office cleared Varian Medical‘s (NYSE:VAR) $1.3B proposed buyout of Sirtex Medical (ASX:SRX), Varian reported today. The companies first announced that they inked a deal for Varian to acquire all of Sirtex’s outstanding shares in January this year. The transaction is slated to close in late May. Sirtex shareholders […]
Varian Medical to pay $1.3B for Sirtex
Varian Medical (NYSE:VAR) yesterday said it agreed to pay nearly $1.3 billion for Australia’s Sirtex Medical (ASX:SRX) and its anti-cancer microspheres. The A$28-per-share offer, which values Sirtex at A$1.59 billion (about $1.28 billion), is slated to close in late May, Palo Alto, Calif.-based Varian said. It’s part of a bid to broaden that company’s oncology portfolio. Sirtex makes […]
Report: Chinese bidders eye Johnson & Johnson’s diabetes biz
Chinese glucose monitor maker Sinocare (SZ:300298) and a sovereign wealth fund there are said to be in the hunt for the diabetes business Johnson & Johnson (NYSE:JNJ) is looking to unload. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, Animas and Calibra Medical diabetes businesses and later elected to […]
PerkinElmer closes $1.3B Euroimmun buy
PerkinElmer (NYSE:PKI) has closed its $1.3 billion deal to buy Euroimmun Medical Laboratory Diagnostics, the scientific instrument-maker reported today. The acquisition, first announced in June, involves Euroimmun’s 2,400 employees and autoimmune testing solutions. The move helps to expand PerkinElmer’s footprint in autoimmune and allergy diagnostic markets. PerkinElmer also reportedly plans to bring Euroimmun’s tech into its well-established […]
CVS Health to buy Aetna in $69B merger
CVS Health (NYSE:CVS) plans to buy health insurer Aetna (NYSE:AET) in a $69 billion merger, according to a report from The New York Times. The deal comes as companies like Amazon (NSDQ:AMZN), which is reportedly trying to launch into the pharmacy business, are looking to change the way that consumers interact with the healthcare industry. The […]
Smith & Nephew deals topical anesthetic gel to Alliance Pharma
Alliance Pharma (LON:APH) has acquired the rights to Smith & Nephew‘s (NYSE:SNN) anesthetic gel Ametop for $7.5 million, according to the specialty pharmaceutical company. The product, which Smith & Nephew has been selling in the U.K., Ireland, New Zealand and Canada for at least 10 years, is designed to numb a patient’s skin before an injection. […]
- 1
- 2
- 3
- …
- 8
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn